One-Alpha

Overview

One-Alpha is the brand name for alfacalcidol, a synthetic vitamin D analogue used primarily to treat calcium metabolism disorders¹. It is classified as a prodrug of calcitriol (1,25-dihydroxyvitamin D), the active form of vitamin D, and is prescribed for conditions like hypocalcemia, secondary hyperparathyroidism, and renal osteodystrophy². Unlike standard vitamin D, alfacalcidol does not require kidney activation, making it suitable for patients with chronic kidney disease (CKD)³. Historically, it was developed in the 1970s to address vitamin D resistance in renal failure patients, building on discoveries of vitamin D metabolism pathways⁴. It helps regulate calcium and phosphate levels, supporting bone health and preventing fractures¹.

Forms and Variations

One-Alpha is available as oral capsules (0.25 mcg, 0.5 mcg, 1 mcg) and oral solutions (2 mcg/ml), with injectable forms for hospital use⁵. Variations include generic alfacalcidol, but One-Alpha refers specifically to the branded product by Leo Pharma⁶. Capsules are preferred for precise dosing in outpatients, while drops suit children or those with swallowing difficulties⁷. Choose oral forms for chronic management; injections for acute hypocalcemia. Bioavailability is high, with capsules absorbed quickly in the small intestine⁸.

Dosage and Administration

Typical starting dose for adults with CKD is 0.25-1 mcg daily, adjusted based on serum calcium and PTH levels². Children receive 0.01-0.03 mcg/kg/day⁹. Administer once daily with or without food, but monitor calcium weekly initially¹⁰. Best practices include pairing with calcium supplements if dietary intake is low, avoiding antacids that bind calcium, and regular blood tests to titrate dose³. Do not exceed 2 mcg/day without supervision¹.

Scientific Research and Mechanism of Action

Alfacalcidol is converted in the liver to calcitriol via 25-hydroxylation, bypassing the kidney"s 1-alpha-hydroxylase step¹¹. It binds vitamin D receptors (VDR) in intestines, bones, and parathyroid glands, enhancing calcium absorption, bone mineralization, and suppressing PTH secretion¹². Key studies show it reduces fracture risk by 20-30% in CKD patients vs. placebo (ALPINE trial)¹³. Meta-analyses confirm PTH suppression superior to calcitriol in dialysis patients¹⁴. Research supports cardiovascular benefits via reduced vascular calcification¹⁵. Current evidence is strong for renal bone disease; ongoing trials explore osteoporosis¹⁶.

Benefits and Potential Uses

Proven benefits include normalizing calcium/phosphate balance, preventing renal osteodystrophy, and lowering PTH in CKD stages 3-5². It improves bone density and reduces fractures in hypoparathyroidism and vitamin D-resistant rickets¹⁷. Potential uses: osteoporosis prevention in elderly, especially with renal impairment; adjunct in psoriasis; supportive in hypophosphatasia¹⁸. Addresses secondary hyperparathyroidism, muscle weakness, and growth retardation in children¹⁹. Long-term use enhances quality of life by minimizing bone pain and hospitalizations¹³.

Side Effects and Risks

Common side effects: hypercalcemia (nausea, vomiting, weakness), pruritus, and fatigue¹. Risks include hypercalciuria leading to kidney stones, ectopic calcification²⁰. Contraindicated in hypercalcemia, vitamin D toxicity, or malabsorption syndromes⁵. Caution in elderly, pregnant women (category C), and those with heart disease due to arrhythmia risk²¹. Monitor serum calcium closely¹⁰.

Interactions and Precautions

Interacts with thiazides (increases hypercalcemia risk), digoxin (arrhythmias), and magnesium antacids (hypomagnesemia)²². Avoid with other vitamin D analogs or high-calcium diets²³. Precautions for renal impairment (dose adjust), pregnancy (fetal hypercalcemia), and lactation⁹. Discontinue 1 week before surgery if hypercalcemia risk; monitor in dialysis patients²⁴.

Impact on Biomarkers

Increases serum calcium (target 2.1-2.4 mmol/L), decreases PTH (50-150 pg/mL goal), and normalizes alkaline phosphatase². Lowers phosphate in some CKD cases; elevates 1,25(OH)2D levels¹¹. Regular monitoring prevents overtreatment¹⁰.

Overdose and Toxicity

Overdose causes hypercalcemia, dehydration, renal failure; symptoms: polyuria, constipation, confusion²⁵. Acute toxicity rare; chronic from >3 mcg/day. Safe upper limit: 2 mcg/day adults. Treat with hydration, calcitonin, or steroids¹.

Disclaimer

The information provided in this document is for educational purposes only and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.